COMP <GO>
ADPT vs TARS // FREE CASH FLOW YIELD
Adaptive Biotechnologies Corporation (NASDAQ) VS. Tarsus Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: ADPT 3
— TARS 6
▲ FREE CASH FLOW YIELD LEADER: TARS
LAST: $25.06 (-5.93%) • MKT CAP: $4.00B
fcf-yield
-1.09%
LAST: $73.32 (-2.04%) • MKT CAP: $3.61B
fcf-yield
-0.61%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADPT VS. TARS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADPT | TARS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -12.50% | -24.10% | +11.60 | ADPT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -1.09% | -0.61% | -0.48 | TARS | /fcf-yield <GO> |
| Operating Margin | -20.60% | -15.70% | -4.90 | TARS | /operating-margins <GO> |
| Net Profit Margin | -21.50% | -14.60% | -6.90 | TARS | /net-margins <GO> |
| Revenue Growth (YoY) | 54.80% | 146.70% | -91.90 | TARS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.32 | 10.19 | -3.87 | TARS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 5/9 | +1.00 | ADPT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.7 | 50.9 | -7.20 | TARS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.00B | $3.61B | $384.5M | ADPT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADPT REV | TARS REV | ADPT GROSS % | TARS GROSS % | ADPT FCF | TARS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $277.0M | $451.4M | 74.2% | — | -$48.9M | -$22.3M |
| FY 2024 | $179.0M | $183.0M | 59.7% | — | -$98.9M | -$84.6M |
| FY 2023 | $170.3M | $17.4M | — | — | -$164.0M | -$117.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADPT // BETA 1.01
TARS // BETA —